Deborah Ibarra
Psychiatric/Mental Health · Doral, FLNPI 1407359946
Payments from drug & device makers
Across 248 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$860
- Axsome Therapeutics, Inc.$843
- Johnson & Johnson$628
- AbbVie$584
- Otsuka America Pharmaceutical, Inc.$260
- plus $2K from 15 others
What the payments were for
- Food & beverage$5,970100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 49 | $1,199 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $860 |
| Axsome Therapeutics, Inc. | 34 | $843 |
| Johnson & Johnson | 19 | $628 |
| AbbVie | 29 | $584 |
| Otsuka America Pharmaceutical, Inc. | 14 | $260 |
| Vanda Pharmaceuticals Inc. | 9 | $236 |
| Lundbeck LLC | 9 | $225 |
| Idorsia Pharmaceuticals US Inc | 6 | $209 |
| Almatica Pharma LLC | 8 | $201 |
| Alkermes, Inc. | 10 | $200 |
| E.r. Squibb & Sons, L.L.C. | 5 | $122 |
| Collegium Pharmaceutical, Inc. | 5 | $103 |
| Biogen | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Neos Therapeutics, LP | 3 | $48 |
| Tempus AI, Inc | 2 | $43 |
| Sage Therapeutics, LLC | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,970 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 42 | $54,185 |
| Vilazodone Hcl | 21 | $2,155 |
| Eszopiclone | 12 | $259 |
| Trazodone Hcl | 23 | $114 |
| Quetiapine Fumarate | 16 | $100 |
| Clonazepam | 21 | $71 |
| Sertraline Hcl | 27 | $68 |
| Escitalopram Oxalate | 17 | $63 |
| Alprazolam | 30 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $628 | $54,18542 claims |
| Almatica Pharma LLCSertraline Hcl | $201 | $6827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Doral
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.